ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trial"

  • Abstract Number: 0001 • ACR Convergence 2022

    12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)

    John Botson1, kenneth saag2, Jeff Peterson3, Katie Obermeyer4, Brian LaMoreaux4, Suneet Grewal5, Amar Majjhoo6, John Tesser7 and Michael Weinblatt8, 1Orthopedic Physicians Alaska, Anchorage, AK, 2University of Alabama at Birmingham, Birmingham, AL, 3Western Washington Arthritis Clinic, Seattle, WA, 4Horizon Therapeutics plc, Deerfield, IL, 5East Bay Rheumatology Medical Group, Inc., San Leandro, CA, 6Shores Rheumatology, PC, Troy, MI, 7Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 8Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
  • Abstract Number: 0297 • ACR Convergence 2022

    Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

    Louis Bessette1, Adriana Kakehasi2, Neil Basu3, David A. Walsh4, Andra Balanescu5, Clifton Bingham6, Andrew Garrison7, Ivan Lagunes8, sander strengholt9, Ralph Lippe10 and Maxime Dougados11, 1Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 2Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, 3University of Glasgow, Glasgow, Scotland, United Kingdom, 4University of Nottingham, Nottingham, United Kingdom, 5University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 6Johns Hopkins University, Baltimore, MD, 7AbbVie, Inc., North Chicago, IL, 8AbbVie, Inc., Mettawa, IL, 9AbbVie, Inc., Abcoude, Netherlands, 10AbbVie, Inc, Wiesbaden, Germany, 11Université de Paris, Paris, France

    Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
  • Abstract Number: 0391 • ACR Convergence 2022

    Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data

    William Tillett1, Alexander Egeberg2, Enikö Sonkoly3, Patricia Gorecki4, Anna Tjärnlund5, Jozefien Buyze6, Sven Wegner7 and Dennis McGonagle8, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, 3Dermatology and Venereology Division, Karolinska Institutet; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 4Janssen-Cilag Ltd, High Wycombe, United Kingdom, 5Janssen-Cilag AB, Solna, Sweden, 6Janssen Pharmaceutica NV, Beerse, Belgium, 7Janssen-Cilag GmbH, Neuss, Germany, 8Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed…
  • Abstract Number: 0746 • ACR Convergence 2022

    Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial

    Ho SO1, Evelyn Chow2, Isaac Cheng1, Xerox Lau2, Tena Li1, Cheuk Chun Szeto2 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
  • Abstract Number: 1035 • ACR Convergence 2022

    Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies

    Philip J Mease1, William Tillett2, Sarah Ohrndorf3, Michelle Perate4, Mary Medysky5, Miriam Zimmermann6, May Shawi7, Emmanouil Rampakakis8, Paul Bird9, Alen Zabotti10, Atul Deodhar11 and Dafna Gladman12, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 3Charité Universitätsmedizin Berlin, Berlin, Germany, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Scientific Affairs, LLC, Seattle, WA, 6Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 9University of New South Wales, Sydney, Australia, 10Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR, 12Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
  • Abstract Number: 1536 • ACR Convergence 2022

    Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR

    Anna-Maria Hoffmann-Vold1, Cathrine Brunborg1, Paolo Airò2, Lidia P. Ananyeva3, László Czirják4, Serena Guiducci5, Eric Hachulla6, MENGTAO LI7, Carina Mihai8, Gabriela Riemekasten9, Petros P. Sfikakis10, Gabriele Valentini11, Otylia Kowal-Bielecka12, Yannick Allanore13 and Oliver Distler8, 1Oslo University Hospital, Oslo, Norway, 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, 3V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 4Medical school of Pécs, Pecs, Hungary, 5University of Firenze, Firenze, Italy, 6University of Lille, Lille, France, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 9University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, 10Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 11Università della Campania “Luigi Vanvitelli”, Napoli, Italy, 12Medical University of Bialystok, Bialystok, Poland, 13Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…
  • Abstract Number: 1829 • ACR Convergence 2022

    Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study

    Lindsay Helget1, Anne Davis-Karim2, James O'Dell1, Ted Mikuls3, Jeff Newcomb1, Maria Androsenko4, Mary Brophy4, Bryant England1, Ryan Ferguson4, Michael Pillinger5, Tuhina Neogi6, Hongsheng Wu4 and Paul Palevsky7, 1University of Nebraska Medical Center, Omaha, NE, 2VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, 5NYU Grossman School of Medicine, New York, NY, 6Boston University School of Medicine, Boston, MA, 7University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh

    Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
  • Abstract Number: 1997 • ACR Convergence 2022

    Effects of Short Chain Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and New Onset Rheumatoid Arthritis

    Rebecca Blank1, Alba Boix-Amoros2, Renuka Nayak3, Anthony Jimenez Hernandez1, Sydney Catron4, Zakwan Uddin4, Erin Reilly5, Andrew Patterson5, Peter Turnbaugh6, Jose Clemente2 and Jose Scher7, 1NYU School of Medicine, New York, NY, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3University of California San Francisco, San Francisco, CA, 4NYU Langone Health, New York, NY, 5Pennsylvania State University, College Park, PA, 6UCSF, San Francisco, 7New York University School of Medicine, New York, NY

    Background/Purpose: The gut microbiome and its metabolites are dysregulated in rheumatoid arthritis. Short chain fatty acids (SCFAs), microbial fermentation byproducts of certain gut microbes, induce…
  • Abstract Number: 2137 • ACR Convergence 2022

    Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis

    Lihi Eder1, Laura Coates2, Peter Nash3, Uta Kiltz4, Ennio Lubrano5, Erin McDearmon-Blondell6, Tianming Gao7 and Alexis Ogdie8, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3School of Medicine, Griffith University, Brisbane, Australia, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 6AbbVie, Inc., Mettawa, IL, 7AbbVie, Inc., North Chicago, IL, 8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
  • Abstract Number: 0003 • ACR Convergence 2022

    Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial

    Toby Maher1, Veronica Tudor2, Peter Saunders3, Michael Gibbons4, Sophie Fletcher5, Helen Parfrey6, Chris Denton7, Rachel Hoyles3, Elizabeth Renzoni2, Maria Kokosi2, Athol Wells2, Deborah Ashby8, Matyas Szigeti8 and Philip Molyneaux8, 1University of Southern California, Los Angeles, CA, 2Royal Brompton Hospital, London, United Kingdom, 3Oxford University Hospitals, Oxford, United Kingdom, 4Royal Devon and Exeter Hospital, Exeter, United Kingdom, 5Southampton University Hospitals, Southampton, United Kingdom, 6Addenbrookes Hospital, Cambridge, United Kingdom, 7University College London, London, United Kingdom, 8Imperial College London, London, United Kingdom

    Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…
  • Abstract Number: 0299 • ACR Convergence 2022

    Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib

    Yoshiya Tanaka1, Tatsuya Atsumi2, Daniel Aletaha3, Robert Landewé4, Beatrix Bartok5, Alena Pechonkina6, Ling Han6, Kahaku Emoto7, Shungo Kano7, Vijay Rajendran8 and Tsutomu Takeuchi9, 1University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 2Hokkaido University, Sapporo, Japan, 3Medical University Vienna, Wien, Austria, 4Amsterdam University Medical Center, Meerssen, Netherlands, 5Gilead Sciences, Inc., La Jolla, CA, 6Gilead Sciences, Foster City, CA, 7Gilead Sciences, K.K., Tokyo, Japan, 8Galapagos NV, Gent, Belgium, 9Keio University and Saitama Medical University, Tokyo, Japan

    Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
  • Abstract Number: 0403 • ACR Convergence 2022

    Efficacy and Safety of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis: 16-Week Results from a Phase 3 Study

    Yu Xue1, Jiankang Hu2, Dongzhou Liu3, Jingyang Li4, Huaxiang Wu5, Chunyu Tan6, Lie Dai7, Mengru Liu8, Hongying Li8 and Hejian Zou1, 1Huashan Hospital affiliated to Fudan University, Shanghai, China, 2Jiangxi Pingxiang People’s Hospital, Shanghai, China, 3Shenzhen People’s Hospital (The Second Clinical Medical College of Jinan University), Shanghai, China, 4Zhuzhou Central Hospital, Shanghai, China, 5The Second Affiliated Hospital Zhejiang University School of Medicine, Shanghai, China, 6West China Hospital of Sichuan University, Shanghai, China, 7Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Shanghai, China, 8Eli Lilly and Company, Shanghai, China

    Background/Purpose: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, has demonstrated efficacy in global clinical trials in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis…
  • Abstract Number: 0763 • ACR Convergence 2022

    Immunogenicity Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

    Vibeke Strand1, Shaun Bender2 and Dorothy McCabe3, 1Stanford University School of Medicine, Stanford, CA, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

    Background/Purpose: The VOLTAIRE trials program compared the safety, efficacy, and immunogenicity of biosimilar BI 695501 with adalimumab reference product (RP) for indications including moderate-severely active…
  • Abstract Number: 1037 • ACR Convergence 2022

    Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies

    Xenofon Baraliakos1, Dafna Gladman2, Soumya Chakravarty3, Cinty Gong4, May Shawi5, Emmanouil Rampakakis6, Kishimoto Mitsumasa7, Enrique R Soriano8 and Philip J Mease9, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 9Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only…
  • Abstract Number: 1549 • ACR Convergence 2022

    Toward Safer Glucocorticoid Therapy

    Xingyu Pan1, Qiongqiong Hou1, Jiahui Xu1, Yake Ma1, Jiawen Li1, Min Li1, Jing Su1, Xuerou Shi1, William Bracken2 and David Katz2, 1WuXi AppTec, Nantong, China, 2Sparrow Pharmaceuticals, Portland, OR

    Background/Purpose: SPI-62 is a potent 11b-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology